Aprea Therapeutics Inc logo

APRE - Aprea Therapeutics Inc News Story

$4.63 0.3  7.2%

Last Trade - 7:25pm

Sector
Healthcare
Size
Small Cap
Market Cap £66.4m
Enterprise Value £1.82m
Revenue £n/a
Position in Universe 5228th / 6851

BUZZ-Aprea Therapeutics: Slumps after blood cancer treatment fails late-stage trial

Mon 28th December, 2020 1:36pm
** Drug developer's shares  APRE.O  tumble 70% to their
record low of $7.25 premarket    
    ** Stock among top pct loser across U.S. exchanges and set
for worst day ever 
    ** Co says its therapy, eprenetapopt in combination with
chemotherapy drug, azacitidine, to treat a type of blood cancer
did not meet main goal in a late-stage trial  urn:newsml:reuters.com:*:nGNX5XmQc3
    ** Co was testing eprenetapopt in combination with
azacitidine versus azacitidine (AZA) alone in patients with the
disease called myelodysplastic syndromes
    ** Data showed a higher complete remission rate in the
experimental arm receiving eprenetapopt with AZA versus the
control arm receiving AZA alone, but did not reach statistical
significance - APRE 
    ** Up to Friday's close, stock had fallen ~45% YTD

 (Reporting by Dania Nadeem in Bengaluru)
 ((Dania.Nadeem@thomsonreuters.com;))
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.